Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...
Even as Biogen weighs strategic options for its biosimilars unit, the group is celebrating an industry first. Biogen’s version of Roche’s autoimmune drug Actemra has won FDA approval, the company said ...
The FDA has approved the first biosimilar version of the interleukin-6 (IL-6) blocker tocilizumab, to be marketed as Tofidence and with indications for rheumatoid arthritis (RA), systemic juvenile ...
SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost management strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results